New ATC codes 2020
| ATC code | ATC level name |
|---|---|
| V09IX13 | methionine (11C) |
| V04CX09 | patent blue |
| V04CX08 | carbon monoxide |
| V04CX07 | edrophonium |
| V04CX06 | hexaminolevulinate |
| V04CX05 | 13C-urea |
| V04CX04 | mannitol |
| V04CX03 | methacholine |
| V04CX02 | folic acid |
| V03AF11 | arginine and lysine |
| S01XA27 | voretigene neparvovec |
| S01LA06 | brolucizumab |
| S01EE51 | latanoprost and netarsudil |
| S01EE06 | latanoprostene bunod |
| S01AA28 | vancomycin |
| R03BB08 | revefenacin |
| R03AL12 | indacaterol, glycopyrronium bromide and mometasone |
| R03AL11 | formoterol, glycopyrronium bromide and budesonide |
| R03AL10 | formoterol and tiotropium bromide |
| R03AK14 | indacaterol and mometasone |
| P02CX03 | moxidectin |
| P01BA07 | tafenoquine |
| N07XX15 | inotersen |
| N06BA14 | solriamfetol |
| N06AX27 | esketamine 2) |
| N05CD14 | remimazolam |
| N02CD03 | fremanezumab |
| L04AX08 | darvadstrocel |
| L04AC18 | risankizumab |
| L04AB07 | opinercept |
| L04AA44 | upadacitinib |
| L04AA43 | ravulizumab |
| L04AA42 | siponimod |
| L04AA41 | imlifidase |
| L03AX21 | elapegademase |
| L02BB06 | darolutamide |
| L01XX68 | belotecan |
| L01XX67 | tagraxofusp |
| L01XX66 | selinexor |
| L01XX65 | alpelisib |
| L01XX64 | entinostat |
| L01XX63 | glasdegib |
| L01XX62 | ivosidenib |
| L01XE57 | fedratinib |
| L01XE56 | entrectinib |
| L01XE54 | gilteritinib |
| L01XE53 | larotrectinib |
| L01XE52 | quizartinib |
| L01XE51 | acalabrutinib |
| L01XC33 | cemiplimab |
| J05AX27 | favipiravir |
| J05AX26 | amenamevir |
| J05AX25 | baloxavir marboxil |
| J05AX24 | tecovirimat |
| J05AR27 | lamivudine, tenofovir disoproxil and dolutegravir |
| J05AR26 | darunavir and ritonavir |
| J05AR25 | lamivudine and dolutegravir |
| J05AP58 | daclatasvir, asunaprevir and beclabuvir |
| J05AP11 | grazoprevir |
| J05AP10 | elbasvir |
| J05AH04 | laninamivir |
| J04AB06 | enviomycin |
| J01XX12 | lefamulin |
| J01GB14 | plazomicin |
| J01AA15 | omadacycline |
| J01AA14 | sarecycline |
| H02CA02 | osilodrostat |
| H01CC03 | elagolix |
| G04CA54 | tamsulosin and tadalafil |
| G01AF55 | econazole, combinations |
| D11AA01 | glycopyrronium |
| D06AX15 | rifamycin |
| D03AX14 | Centella asiatica herba |
| C10BX17 | rosuvastatin and ramipril |
| C10BX16 | rosuvastatin and fimasartan |
| C10BA09 | rosuvastatin and fenofibrate |
| C10BA08 | atorvastatin and omega-3 fatty acids |
| C10BA07 | rosuvastatin and omega-3 fatty acids |
| C10AX15 | bempedoic acid |
| C09DX07 | irbesartan, amlodipine and hydrochlorothiazide |
| C09DB09 | fimasartan and amlodipine |
| C09BX04 | perindopril, bisoprolol and amlodipine |
| C08CA51 | amlodipine and celecoxib |
| B06AX01 | crizanlizumab |
| B06AX 1) | Other hematological agents |
| B03XA06 | luspatercept |
| B03AA12 | ferrous sodium citrate |
| B02AB05 | ulinastatin |
| B01AF04 | betrixaban |
| A16AB19 | pegvaliase |
| A10BK06 | sotagliflozin |
| A07AA13 | rifamycin |
| A03FA09 | mosapride |
| A03BB06 | homatropine methylbromide |
| A02BD15 | vonoprazan, amoxicillin and metronidazole |
| A02BD14 | vonoprazan, amoxicillin and clarithromycin |
| A02BD13 | rabeprazole, amoxicillin and metronidazole |
| A02BD12 | rabeprazole, amoxicillin and clarithromycin |
| A02BC08 | vonoprazan |
1) New 4th level
2) Nasal formulations indicated for major depressive disorders. Parenteral formulations are classified in N01AX14.
2) Nasal formulations indicated for major depressive disorders. Parenteral formulations are classified in N01AX14.
Last updated: 2019-12-20